323 related articles for article (PubMed ID: 29431852)
1. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.
Anton RF; Latham PK; Voronin KE; Randall PK; Book SW; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2018 Apr; 42(4):751-760. PubMed ID: 29431852
[TBL] [Abstract][Full Text] [Related]
2. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.
Ray LA; Green R; Enders C; Leventhal AM; Grodin EN; Li G; Lim A; Hartwell E; Venegas A; Meredith L; Nieto SJ; Shoptaw S; Ho D; Miotto K
Am J Psychiatry; 2021 Sep; 178(9):818-828. PubMed ID: 34080890
[TBL] [Abstract][Full Text] [Related]
5. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.
Kahler CW; Cioe PA; Tzilos GK; Spillane NS; Leggio L; Ramsey SE; Brown RA; O'Malley SS
Alcohol Clin Exp Res; 2017 Jun; 41(6):1201-1211. PubMed ID: 28401564
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.
Fridberg DJ; Cao D; Grant JE; King AC
Alcohol Clin Exp Res; 2014 Oct; 38(10):2622-9. PubMed ID: 25335648
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
9. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
10. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
[TBL] [Abstract][Full Text] [Related]
11. Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
Witkiewitz K; Roos CR; Mann K; Kranzler HR
Alcohol Clin Exp Res; 2019 Nov; 43(11):2395-2405. PubMed ID: 31436886
[TBL] [Abstract][Full Text] [Related]
12. Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.
King A; Cao D; Zhang L; Rueger SY
Addiction; 2013 Oct; 108(10):1836-44. PubMed ID: 23714324
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
[TBL] [Abstract][Full Text] [Related]
14. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
15. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
16. Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
Lim AC; Roche DJO; Ray LA
J Stud Alcohol Drugs; 2018 Nov; 79(6):918-928. PubMed ID: 30573023
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.
King A; Cao D; Vanier C; Wilcox T
Alcohol Clin Exp Res; 2009 Jun; 33(6):1044-50. PubMed ID: 19302083
[TBL] [Abstract][Full Text] [Related]
18. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
20. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
